Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new ...

Weightwatchers and bariatric surgery had limited effects on the obese brain, but GLP-1s like Ozempic may mean new hope in ...

A growing number of users say Ozempic is rewiring their taste buds in ways they never saw coming. Many have complained about unexpected side effects like the Ozempic butt, the Ozempic mouth, and the ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can naturally mimic the effects of semaglutides.

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

ORLANDO -- Fracture risk may be higher after bariatric surgery than after treatment with weight-loss drugs, propensity-score ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

People on GLP-1 medication seem to be adding more protein to their diets, further increasing demand for chicken and beef at a ...

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.